Results 41 to 50 of about 14,163 (275)

Soluble Neprilysin in the General Population: Clinical Determinants and Its Relationship to Cardiovascular Disease

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019
Background Neprilysin is a metalloprotease involved in proteolysis of numerous peptides, including natriuretic peptides, and is of prognostic and therapeutic importance in heart failure with reduced ejection fraction.
Yogesh N. V. Reddy, Seethalakshmi R. Iyer, Christopher G. Scott, Richard J. Rodeheffer, Kent Bailey, Gregory Jenkins, Anthony Batzler, Margaret M. Redfield, John C. Burnett, Naveen L. Pereira   +9 more
doaj   +1 more source

Combined drug sacubitril/valsartan -a new era of treatment of chronic heart failure

Медицинский совет, 2020
The article describes the possibility of using a new class of angiotensin II/neprilysin receptor inhibitor - sacubitrile/valsartan for the treatment of chronic heart failure (CHF). The role of the natriuretic peptide system in the pathogenesis of CHF and
V. S. Nikiforov
doaj   +1 more source

The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study [PDF]

, 2017
Aims: Progressive aortic stiffening eventually leads to left ventricular (LV) hypertrophy and heart failure if left untreated. Anti-hypertensive agents have been shown to reverse this to some extent. The effects of sacubitril/valsartan (LCZ696), a dual-
Aichner, Solveig, Albrecht, Diego, Bremerich, Jens, Delles, Christian, Freyhardt, Patrick, Heye, Tobias, Hrabak-Paar, Maja, Janka, Rolf, Keicher, Christian, Khder, Yasser, Langenickel, Thomas, Mayr, Michael, Ott, Christian, Schmieder, Roland E., Wagner, Frank, Yates, Denise   +15 more
core   +1 more source

Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure

New England Journal of Medicine, 2019
BACKGROUND Acute decompensated heart failure accounts for more than 1 million hospitalizations in the United States annually. Whether the initiation of sacubitril–valsartan therapy is safe and effective among patients who are hospitalized for acute ...
E. Velazquez, D. Morrow, A. DeVore, Carol I. Duffy, A. Ambrosy, K. Mccague, Ricardo A. Rocha, E. Braunwald   +7 more
semanticscholar   +1 more source

Neprilysin Inhibition Improves Intravenous but not Oral Glucose-Mediated Insulin Secretion via GLP-1R Signaling in Mice with Beta-Cell Dysfunction.

American Journal of Physiology. Endocrinology and Metabolism, 2022
Type 2 diabetes is associated with upregulation of neprilysin, a peptidase capable of cleaving glucoregulatory peptides such as glucagon-like peptide-1 (GLP-1).
N. Esser, S. Mongovin, Jacqueline H Parilla, Breanne M Barrow, T. Mundinger, Brendy S. Fountaine, Megan J Larmore, J. J. Castillo, R. Akter, R. Hull, S. Zraika   +10 more
semanticscholar   +1 more source

IL-33 ameliorates Alzheimer’s disease-like pathology and cognitive decline [PDF]

, 2016
Alzheimer’s disease (AD) is a devastating condition with no known effective treatment. AD is characterized by memory loss as well as impaired locomotor ability, reasoning, and judgment.
Chan, Ivy C. W., Cheung, Tom H., Fu, Amy K. Y., Fu, Wing-Yu, Hung, Kwok-Wang, Ip, Nancy Y., Liew, Foo Y., Mak, Deejay S. Y., Yuen, Michael Y. F., Zhang, Baorong, Zhou, Xiaopu   +10 more
core   +1 more source

Neprilysin inhibition in chronic kidney disease [PDF]

Nephrology Dialysis Transplantation, 2014
Despite current practice, patients with chronic kidney disease (CKD) are at increased risk of progression to end-stage renal disease and cardiovascular events. Neprilysin inhibition (NEPi) is a new therapeutic strategy with potential to improve outcomes for patients with CKD.
Judge, P, Haynes, R, Landray, M, Baigent, C   +3 more
openaire   +3 more sources

Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes

Diabetes, obesity and metabolism, 2022
Sacubitril/valsartan is a neprilysin‐inhibitor/angiotensin II receptor blocker used for the treatment of heart failure. Recently, a post‐hoc analysis of a 3‐year randomized controlled trial showed improved glycaemic control with sacubitril/valsartan in ...
N. J. Wewer Albrechtsen, Andreas Møller, Christoffer Martinussen, L. Gluud, E. Rashu, Michael M Richter, P. Plomgaard, J. Goetze, Sasha A. S. Kjeldsen, Lasse H. Hansen, F. Gustafsson, C. Deacon, J. Holst, S. Madsbad, K. N. Bojsen-Møller   +14 more
semanticscholar   +1 more source

Blockade of the Neprilysin and Angiotensin Ameliorates Oxidative Stress in the Cardiovascular Target Tissues of Dexamethasone-induced Hypertensive Rats

Haseki Tıp Bülteni, 2020
Aim:The imbalance between production of reactive oxygen species and antioxidant defense determines the degree of oxidative toxicity and severity of subsequent myocardial damage.We aimed to evaluate the anti-oxidative effects of neprilysin and angiotensin
Duygun Altıntaş Aykan, Muhammed Seyithanoğlu, Nadire Eser, Burak Tanrıverdi, Yaman Selma   +4 more
doaj   +1 more source

Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence [PDF]

The Korean Journal of Internal Medicine, 2020
Heart failure (HF) is a growing health concern in aging societies worldwide. Sacubitril/valsartan is changing the real-world treatment in the whole spectrum of HF.
Hong-Mi Choi, Mi-Seung Shin
doaj   +1 more source